MY173548A - Fxa variant compositions - Google Patents

Fxa variant compositions

Info

Publication number
MY173548A
MY173548A MYPI2016700985A MYPI2016700985A MY173548A MY 173548 A MY173548 A MY 173548A MY PI2016700985 A MYPI2016700985 A MY PI2016700985A MY PI2016700985 A MYPI2016700985 A MY PI2016700985A MY 173548 A MY173548 A MY 173548A
Authority
MY
Malaysia
Prior art keywords
fxa variant
variant compositions
compositions
fxa
hemostasis
Prior art date
Application number
MYPI2016700985A
Other languages
English (en)
Inventor
Michael Anthony Jankowski
Keith A Johnson
Wendy Carol Piacenza
Jason C Rouse
Michael Shamashkin
Penelope Jane Sharpe
Mary Beth Switzer
Stacey B Weston
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY173548A publication Critical patent/MY173548A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
MYPI2016700985A 2013-09-24 2014-09-16 Fxa variant compositions MY173548A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
MY173548A true MY173548A (en) 2020-02-04

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016700985A MY173548A (en) 2013-09-24 2014-09-16 Fxa variant compositions

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN105579468A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
ES2875538T3 (es) 2016-06-17 2021-11-10 Alexion Pharma Inc Preparación de derivados del factor Xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
PL2300497T3 (pl) 2008-06-24 2013-02-28 Octapharma Ag Sposób oczyszczania czynnika krzepnięcia VIII
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
KR20110114587A (ko) 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
SI2591006T1 (sl) * 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
WO2015066606A2 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
PT3096779T (pt) 2014-01-24 2020-02-21 Pfizer Composições e métodos para tratamento de hemorragia intracerebral

Also Published As

Publication number Publication date
HK1218760A1 (zh) 2017-03-10
IL244258A0 (en) 2016-04-21
US9757434B2 (en) 2017-09-12
US20210106658A1 (en) 2021-04-15
AU2014326257B2 (en) 2017-08-10
CN112195169A (zh) 2021-01-08
US10660946B2 (en) 2020-05-26
KR20160044034A (ko) 2016-04-22
IL279396A (en) 2021-01-31
BR112016005899A2 (pt) 2017-09-26
CN105579468A (zh) 2016-05-11
TW201524996A (zh) 2015-07-01
PE20160877A1 (es) 2016-09-11
MX373466B (es) 2020-05-25
BR112016005899A8 (pt) 2018-02-06
TWI631134B (zh) 2018-08-01
CA2924981A1 (en) 2015-04-02
US20150182604A1 (en) 2015-07-02
AR097732A1 (es) 2016-04-13
AU2014326257A1 (en) 2016-03-10
SA516370751B1 (ar) 2018-04-05
MX2016003871A (es) 2016-08-04
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
JP6429885B2 (ja) 2018-11-28
RU2648144C2 (ru) 2018-03-22
SG11201601221XA (en) 2016-04-28
WO2015044836A1 (en) 2015-04-02
RU2016108608A (ru) 2017-10-26
US20170333535A1 (en) 2017-11-23
JP2016535071A (ja) 2016-11-10
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
IL240902A0 (en) Powdered formulation containing thrombin and fibrinogen
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
DK2994173T3 (en) Wound healing and tissue engineering
IL320195A (en) Methods and compositions containing purified recombinant polypeptides
MX362155B (es) Combinaciones de alquilamidotiazoles y sustancias aromaticas.
SG11201508167PA (en) Therapeutic compositions and uses thereof
AU343215S (en) Merchandiser
IL245647A0 (en) surgical gauze
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
IL240924B (en) Antagonistic peptide to cxcr4 and cytarabine for the treatment of myeloid leukemia
DK3007717T3 (da) Peptider med antagonistiske aktiviteter mod naturlig cxcr4
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
PT2948160T (pt) Composições que contêm sulfato de condroitina, nattokinase e compostos de sulfidrilo para melhorar a biodisponibilidade de sulfato de condroitina
IL279396A (en) Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins
GB2515113B (en) Surgical table and method of operating the same
LT2854841T (lt) Kalikreino 1 iš žmogaus audinio glikozilinimo izoformos
IL235035A0 (en) A preparation to prevent an effect on blood vessels in the treatment of blood loss and anemia
PL405129A1 (pl) Nowe peptydomimetyki o aktywności antyangiogennej
MX2015007625A (es) Composiciones sellantes.
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
BR112015008704A2 (pt) composição fungicida compreendendo mancozeb e clorotalonil
GB201310678D0 (en) Surgical tables and methods of operating the same
FR3049867B1 (fr) Composition hemostatique et cicatrisante
GB201319459D0 (en) Karaoke collaboration for those in care and their families and trusted others